Undisclosed SMART Dual CAR T / Cellectis - LARVOL DELTA

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors (GlobeNewswire) - "Cellectis...published an article in Molecular Therapy demonstrating TALEN-mediated gene editing capabilities for design of SMART DUAL CAR T-cells, which efficiently target immunotherapy recalcitrant solid tumors while mitigating potential safety risks....Our allogeneic SMART CAR T-cells are designed to express a constitutive CAR, targeting FAP+ CAFs in solid tumors, and a second inducible CAR, expressed only in the presence of FAP+ CAFs and targeting the tumor associated antigen (TAA) named mesothelin. The resultant SMART Dual CAR T-cells efficiently infiltrate and efficiently target triple-negative breast tumors in physiologically relevant mice models, with no observable on-target, off-tumor toxicity."

Preclinical • Triple Negative Breast Cancer